Brose MS, Robinson BG, Sherman SI, Jarzab B, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 2022 Oct 19. doi: 10.1002/cncr.34493.
PMID: 36259380